Tracer library / [177Lu]Lu-PSMA-10

[177Lu]Lu-PSMA-10

Also written as [177Lu]Lu-PSMA-10; [Lu-177]Lu-PSMA-10

Radionuclide: Lu-177 t½ 9585 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Prostate cancer

What it is

Compound class: Urea-based PSMA-targeted DOTA-conjugated peptide inhibitor (Glu-urea-Glu)
Target / mechanism: Prostate-specific membrane antigen (PSMA)-targeted urea-based inhibitor PMID 33638060
Clinical application: Prostate cancer imaging/therapy research (LNCaP xenograft model) PMID 33638060
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	custom manifold	HPLC	—	96.4 ± 2.2%	PSMA-10 (1) DOTA-conjugated precursor	33638060 2021 EJNMMI Radiopharm Chem

Need this precursor?We can point you to suppliers for [177Lu]Lu-PSMA-10, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityOsmolalityMolar activityMetal impuritiesLu-177m

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Lu-177 preparation -> Lu-177m content (rule); therapeutic radiopharmaceutical -> osmolality (rule); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [177Lu]Lu-PSMA-10.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with Lu-177. Compound class inferred from precursor name (not stated outright) -- PMID 33638060: 'PSMA-10 (1) DOTA-conjugated precursor'. Stage set/updated at stage 39 from PMID 33638060: 'In vivo studies as well as μSPECT/CT scans were conducted with male LNCaP tumor xenograft-bearing CB17-SCID mice.'.